774-52-7

Usage

Type

Synthetic compound.

Use

Induce Parkinson's disease-like symptoms in animal models for scientific research.

Toxicity

Potent neurotoxin.

Effects on the brain

Causes irreversible damage to the dopaminergic system.

Symptoms

Tremors, rigidity, and bradykinesia (slowness of movement).

Metabolism

Metabolized in the body to form MPP+.

Active toxic agent

MPP+ disrupts mitochondria and leads to cell death.

Significance

Discovery of MPTP's ability to induce Parkinson's-like symptoms has advanced our understanding of the disease and contributed to the development of new treatments and therapies.

InChI:InChI=1/C12H17N/c1-13-9-7-12(8-10-13)11-5-3-2-4-6-11/h2-6,12H,7-10H2,1H3

Upstream product

• 771-99-3 4-phenylpiperidine 
• 74-88-4 methyl iodide 
• 4972-68-3 1-methyl-4-phenyl-piperidin-4-ol 
• 3627-62-1 1-methyl-4-phenyl-piperidine-4-carbonitrile 
• 50-00-0 formaldehyd 
• 28289-54-5 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine 
• 546-68-9 titanium(IV) isopropylate 
• 67-56-1 methanol 
• 1445-73-4 1-Methyl-4-piperidone 
• 106-37-6 1.4-dibromobenzene 
• 854629-88-2 4-ethoxymethoxy-2-(2-ethoxymethoxy-ethyl)-2-phenyl-butyronitrile 
• 70179-05-4 2-phenyl-4-vinyloxy-2-(2-vinyloxy-ethyl)-butyronitrile 
• 100119-73-1 1,5-dichloro-3-cyano-3-phenylpentane 
• 10469-27-9 α,α-bis(2-hydroxyethyl)phenylacetonitrile 

Downstream Products

• 121233-57-6 1,1'-dimethyl-4,4'-diphenyl-1,1'-butanediyl-bis-piperidinium; dibromide 
• 121812-58-6 1,1'-dimethyl-4,4'-diphenyl-1,1'-pentanediyl-bis-piperidinium; dibromide 
• 884-00-4 1-ethyl-1-methyl-4-phenyl-piperidinium; iodide 
• 141642-80-0 4-Phenyl-piperidine-1-carbodithioic acid cyclohexyl ester 
• 113237-07-3 4-Phenyl-piperidine-1-carboxylic acid 2-trimethylsilanyl-ethyl ester 
• 141642-79-7 4-Phenyl-piperidine-1-carbodithioic acid propyl ester 
• 111313-24-7 4-Phenyl-piperidine-1-carbodithioic acid methyl ester 
• 454482-12-3 4-(1-methyl-4-piperidyl)-phenylamine 
• 114980-40-4 N-methyl-4-phenyl-2-piperidinone 
• 1196482-62-8 C₁₂H₁₅NO₂ 
• 354813-48-2 methyl 4-(1-methylpiperidin-4-yl)benzoate 
• 1071756-46-1 C₁₃H₁₉NO 
• 1276024-93-1 (4-(1-methylpiperidin-4-yl)phenyl)carbaldehyde 
• 28286-03-5 1-methyl-4-(4-nitrophenyl)-piperidine 

Relevant academic research and scientific papers

Iron-Catalyzed Methylation Using the Borrowing Hydrogen Approach

A general iron-catalyzed methylation has been developed using methanol as a C1 building block. This borrowing hydrogen approach employs a Kn?lker-type (cyclopentadienone)iron carbonyl complex as catalyst (2 mol %) and exhibits a broad reaction scope. A variety of ketones, indoles, oxindoles, amines, and sulfonamides undergo mono- or dimethylation in excellent isolated yields (>60 examples, 79% average yield).

Pyrazolo [3,4 - the b] pyridine and [...] composition preparation method and use of (by machine translation)

The present invention provides a pyrazolo [3,4 - the b] pyridine and [...] compound of preparation and use, in particular, the present invention provides a following formula (I) compounds are shown, wherein the definition of each group as described in the specification. The compounds of the invention has excellent tyrosine kinase inhibiting activity, so can be used for preparing a series of treating diseases associated with the tyrosine kinase activity of the drug. (by machine translation)

NOVEL INHIBITORS

The invention relates to novel pyrrolidine derivatives of formula (I): wherein R1, R2 and R3 are as defined herein, as inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5). QC catalyzes the intramolecular cyclization of N-terminal glutamine residues into pyroglutamic acid (5-oxo-prolyl, pGlu*) under liberation of ammonia and the intramolecular cyclization of N-terminal glutamate residues into pyroglutamic acid under liberation of water.

Interactions of 1-methyl-3-phenylpyrrolidine and 3-methyl-1-phenyl-3-azabicyclo[3.1.0]hexane with monoamine oxidase B

The parkinsonian inducing agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its corresponding five-membered ring analogue 1-methyl-3-phenyl-3-pyrroline are cyclic tertiary allylamines and good substrates of monoamine oxidase B (MAO-B). The MAO-B catalyzed 2-electron α-carbon oxidation of this class of substrates appears to be dependent on the presence of the allylic π-bond since the corresponding saturated piperidinyl analogue of MPTP is reported not to be an MAO-B substrate. The only saturated cyclic tertiary amine known to act as an MAO-B substrate is the 3,4-cyclopropyl analogue of MPTP, 3-methyl-6-phenyl-3-azabicyclo[4.1.0]heptane. As part of our ongoing studies we have examined the MAO-B substrate properties of the corresponding pyrrolidinyl analogue, 1-methyl-3-phenylpyrrolidine, and the 3,4-cyclopropyl analogue, 3-methyl-1-phenyl-3-azabicyclo[3.1.0]hexane. The results document that both the pyrrolidinyl analogue [Km = 234 μM; Vmax = 8.37 nmol/(min-mg mitochondrial protein)] and the 3,4-cyclopropyl analogue [Km = 148 μM; Vmax = 16.9 nmol/(min-mg mitochondrial protein)] are substrates of baboon liver mitochondrial MAO-B. We also have compared the neurotoxic potential of these compounds in the C57BL/6 mouse. The results led us to conclude that these compounds are not MPTP-type neurotoxins.

The prediction of1H chemical shifts in amines: A semiempirical and ab initio investigation

Twenty one conformationally fixed amines and their N,N-dimethyl derivatives were obtained commercially or synthesized. These included cis and trans 4-o-butyl cyclohexylamine, 2-exo and 2-endo norbornylamine, 2-adamantylamine, 4-phenylpiperidine, 1-napthyl

SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE

The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.

QUINOLINE- AND ISOQUINOLINE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF

Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, methods of using compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions comprising compounds exhibiting ATP-utilizing enzyme inhibitory activity, are disclosed.

Substituted alkylamine derivatives and methods of use

Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Substituted amine derivatives and methods of use

Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.

Dipeptide nitrile cathepsin K inhibitors

Dipeptide nitrile Cathepsin K inhibitors of formula I, and pharmaceutically acceptable salts or esters thereof In which R1 and R2 are independently H or C1-C7lower alkyl, or R1 and R2 toget